Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease (TIBEC)

NCT07681297 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT07681297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07681297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease (TIBEC)
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
August 31, 2028
Enrollment
154 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor cancer, breast cancer, cns disease, triple-negative breast cancer (tnbc)